Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)
| Autor: | George Nahas, Lazaros J. Lekakis, Mark Goodman, Antonio M. Jimenez, Trent P Wang, Amer Beitinjaneh, Krishna V. Komanduri, Denise Pereira |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment T-Lymphocytes Encephalopathy Antigens CD19 Cell- and Tissue-Based Therapy Filgrastim Gastroenterology Immunotherapy Adoptive 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine Humans B cell Bone Marrow Transplantation Chemotherapy Biological Products Receptors Chimeric Antigen business.industry Incidence Bone marrow failure Hematology medicine.disease Lymphoma Cytokine release syndrome medicine.anatomical_structure Treatment Outcome Oncology 030220 oncology & carcinogenesis Myelodysplastic Syndromes Absolute neutrophil count business 030215 immunology medicine.drug |
| Zdroj: | Leukemialymphoma. 61(4) |
| ISSN: | 1029-2403 |
| Popis: | Anti-CD19 Chimeric Antigen Receptor T cells (CAR-T) have shown dramatic efficacy in treating refractory aggressive B cell Lymphomas leading to FDA approval of axicabtagene ciloleucel and tisagenlecleucel. While long-term remission rate for both is higher than 33%, this treatment is associated with life-threatening complications including cytokine-release syndrome, encephalopathy, and lethal cerebral edema. Here we describe a case series of bone marrow failure syndromes with or without co-existing clonal myelodysplastic syndrome. Bone marrow failure was defined as absolute neutrophil count (ANC) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|